Case report finds pathological response to pembrolizumab in recurrent liposarcoma, suggesting tumor microenvironment may influence outcomes.
This is the first reported case of recurrent retroperitoneal DDLPS with high TMB achieving pCR to pembrolizumab. High TMB and high TAM density in the tumor microenvironment may be predictive biomarkers for the response to ICIs in DDLPS.
No takes yet. Share an insight, caveat, or question.
Ariizumi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: